Линкомицин Эколинком

Quick links

Choose a section

Quick links to important sections

Advertisements

Линкомицин Эколинком

Selected form

Advertisements
Advertisements

Overview of Линкомицин Эколинком

Property Description
Active ingredient Lincomycin (INN)
Form Solution for injection, Hard capsules
Pharmacological class Lincosamide antibiotic
General purpose Resolve serious bacterial infections
Origin Derived from natural fermentation

Линкомицин Эколинком is a prescription-only medicinal product, defined by its active component, Lincomycin, which is used to treat serious bacterial infections. This medicine belongs to the Lincosamide class of antibiotics, a group chemically distinct from penicillins and cephalosporins, allowing it to offer a therapeutic option when specific bacterial strains are resistant to more common treatments.


What Type of Medicine is Линкомицин Эколинком?

Линкомицин Эколинком is classified as a single-ingredient antibiotic containing Lincomycin (as the hydrochloride salt), placing it within the Lincosamide pharmacological class. The active substance, Lincomycin, is not fully synthetic, but is instead derived from a natural fermentation product of the soil bacterium Streptomyces lincolnensis. This specific origin gives it a unique biochemical action that targets key bacterial components.


Composition and General Therapeutic Purpose

The medication is offered in two primary pharmaceutical preparations: a sterile solution for injection intended for parenteral administration in acute cases, and hard capsules for oral ingestion. The drug is a single-ingredient product, containing only Lincomycin and necessary inert pharmaceutical excipients or an aqueous vehicle. The general therapeutic purpose is to resolve serious infections caused by specific vulnerable microorganisms, including Gram-positive aerobes and anaerobic bacteria common in deep tissue infections. The drug utilizes a bacteriostatic effect, which halts bacterial growth and multiplication, thereby supporting the body’s natural immune system in clearing the infection.

Regulatory References

  1. NIH DailyMed (Lincomycin injection)
Advertisements

What side effects are possible with Линкомицин Эколинком?

Possible Side Effects and Safety Information

The safety profile of Линкомицин Эколинком (Lincomycin) is based on official government regulatory classifications of adverse reactions, which are grouped by frequency and affected body system.


Adverse Reaction Classification

Classification Examples of Reactions
Common Diarrhea, nausea, vomiting, abdominal pain, rash, and itching (pruritus).
Rare Aplastic anemia, renal dysfunction, and cardiopulmonary arrest (associated with rapid IV administration).
Frequency Not Known Pseudomembranous colitis, severe allergic reactions (e.g., anaphylaxis), agranulocytosis, and severe skin reactions (SCARs).

Adverse effects most frequently involve the Gastrointestinal System, followed by the Blood and Lymphatic System and Immune System disorders.


Serious Adverse Reactions and Safety Constraints

The label-documented serious risks include Pseudomembranous Colitis (Clostridium difficile Associated Diarrhea, CDAD), which can occur even weeks after treatment cessation, and Severe Hypersensitivity Reactions.

Safety considerations for specific groups are documented. Caution is advised for patients with a history of colitis or severe impairment of hepatic or renal function. Certain injectable formulations containing benzyl alcohol are associated with specific risks in neonates, as noted in the regulatory documents. The risk of hypotension and cardiac events is linked to the speed of intravenous administration and is not solely a feature of the drug itself. Lincomycin also possesses neuromuscular blocking properties, a factor noted in the official safety profile.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

This information is based strictly on authoritative government regulatory documents concerning Lincomycin overdose.

Overdose with Lincomycin (Линкомицин Эколинком) is primarily associated with an intensification of known adverse effects, particularly severe gastrointestinal disturbances (abdominal pain, vomiting, and diarrhea).

Life-Threatening Risks

The most serious documented risk is the potential for severe cardiopulmonary reactions, including cardio-respiratory arrest and profound hypotension (low blood pressure). These severe outcomes are explicitly linked to rapid intravenous administration (infusion at a concentration or rate greater than recommended).

Emergency Actions

If overdose is suspected, treatment with Lincomycin must be discontinued immediately, and the patient must seek urgent medical attention or proceed to the nearest hospital.

Management is symptomatic and supportive. Regulatory information confirms that no specific antidote is known for Lincomycin. Standard drug removal procedures, such as hemodialysis and peritoneal dialysis, are documented as poorly effective.

Population-Specific Consideration

Patients with severe impairment of renal and/or hepatic (liver) function are at a heightened risk for drug accumulation due to a prolonged half-life, which may increase the likelihood or severity of toxicity.

Advertisements

Therapeutic Uses of Линкомицин Эколинком

What Линкомицин Эколинком Treats: Main Uses and Benefits

Линкомицин Эколинком is commonly used in situations involving the management of serious bacterial infections. The core benefit is that it assists in addressing infections caused by susceptible organisms in contexts involving complicated or persistent manifestations.

Addressing Severe Deep-Seated Infections

This medicine is applied for managing symptoms related to inflammatory or irritative states in dense or enclosed tissues. This domain covers conditions presenting with systemic or localized discomfort, such as severe bone and joint infections (like osteomyelitis and septic arthritis). The medication contributes to easing the overall symptom load associated with acute or disruptive episodes.

Therapeutic Option for Penicillin Allergy

Линкомицин Эколинком is considered relevant as a crucial alternative therapy for adult and pediatric patients (1 month and older) who require treatment for serious susceptible infections but have a known allergy to penicillin-class antibiotics. This medication may assist with maintaining functional stability during serious episodes and contributes to improved comfort during periods of heightened symptoms. It supports patients during difficult episodes by easing distress.


Quick Fact: Focus on Managing Symptoms Related to Deep-Seated Pain


Advertisements

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Линкомицин Эколинком (Lincomycin) is an antibiotic reserved for serious bacterial infections where less toxic agents are inappropriate. It should not be used for nonbacterial infections, such as most upper respiratory tract infections, or for the treatment of meningitis because drug levels in the cerebrospinal fluid may be inadequate.

Classification Population/Condition
Contraindicated Patients with known hypersensitivity to lincomycin or clindamycin (due to potential for cross-allergenicity).
Use with Caution Individuals with a history of gastrointestinal disease, particularly colitis, due to the risk of severe diarrhea.
Special Consideration Patients with severe hepatic or renal impairment; dosage adjustment and monitoring are required as the drug's half-life is prolonged.
Age Restriction Benzyl alcohol-containing injectable formulations should be used in neonates only if strictly necessary and should be limited in children under 3 years old.
Pregnancy/Lactation Pregnancy: Use is limited to when clearly needed. Lactation: Nursing should be discontinued or the drug should be stopped, considering the importance of the medicine to the mother, as the drug is excreted in breast milk.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Lincomycin (Линкомицин Эколинком) around documented pharmacodynamic constraints and exposure-modifying factors. This section outlines the specific prohibitions and restrictions noted in government labeling.

Documented Pharmacodynamic and Procedural Interactions

Classification Interacting Entity Interaction Outcome Restriction/Constraint
Contraindicated Co-administration Erythromycin and related macrolides Pharmacodynamic antagonism (reduced efficacy) Co-administration must not occur.
Pharmacodynamic Enhancement Neuromuscular Blocking Agents Enhanced action due to intrinsic neuromuscular blocking properties Use requires monitoring/caution.
Physical Incompatibility Novobiocin and Kanamycin Precipitate formation/physical incompatibility in solution Must not be physically mixed for injection.

Exposure Modification and Population Notes

The serum half-life of Lincomycin is officially documented to increase in the presence of abnormal hepatic function or severe impairment of renal function. This physiological interaction results in an increased risk of systemic drug accumulation. For injectable solutions, the presence of the preservative Benzyl Alcohol is noted as an additional factor that may carry an independent risk of accumulation, particularly in the infant population or those with underlying liver or kidney impairment, according to official labeling.

Advertisements

Mechanism of Action

Targeted Blockade of Bacterial Protein Synthesis

This drug works by engaging a core process inside susceptible bacteria: protein synthesis. It achieves this by precisely binding to the 50S subunit of the bacterial ribosome , acting as an inhibitor to physically stop the assembly of new protein chains. This critical interaction interferes with the translocation step of elongation, thereby interrupting the fundamental cellular machinery that bacteria use to construct the necessary structural and functional proteins.

Inhibition of Microbial Proliferation

The blockade of essential structural and functional proteins initiates a cascade that leads to the inhibition of bacterial growth and division. This mechanism is characterized by its selectivity for the bacterial ribosome, which differs structurally from human ribosomes. This focused action on the microbial proliferation pathway results in the physiological consequence of a reduced concentration of viable bacteria within the body, stemming directly from the drug's mechanism of action.

Advertisements

Dosage and Administration Information

How to Use Линкомицин Эколинком: Administration Guidelines

The usage of Lincomycin (Линкомицин Эколинком) is defined by a set of structured administration rules specifying the required route, dose, frequency, and preparation steps.


Administration Scope

The medicine is administered either orally (as a hard capsule) or parenterally (as an Intramuscular or Intravenous injection solution).

Category Administration Principle
Adult Oral Dosing 500 mg every 8 hours for severe infections; 500 mg every 6 hours for very severe infections.
Adult IM Dosing 600 mg every 24 hours (serious) or every 12 hours (more severe).
Adult IV Dosing 600 mg to 1 gram every 8 to 12 hours, not to exceed 8 grams per day in divided doses.
Oral Timing Capsules should be taken preferably 1 to 2 hours before or after a meal to optimize drug absorption.
IV Preparation The injection solution must be diluted prior to intravenous infusion.
Age/Impairment Rules For pediatric patients (over 1 month), dosing is weight-based (e.g., 10 to 20 mg/kg/day). Severe renal/hepatic impairment requires dose reduction to approximately 25% to 30% of the usual dose.
Duration Treatment for infections caused by beta-hemolytic streptococci must be continued for a minimum of 10 full days.

Procedural Structure

Administration protocols require that the IV solution must not be administered as an undiluted bolus injection. The diluted IV dose must be infused slowly over a period of at least 60 minutes (1 hour), and the infusion rate must not exceed 1 gram per hour.

This structured use protocol defines the delivery method, the exact numerical dose and interval, and the specific conditions for preparation and patient adjustment, ensuring the medicine is administered according to standardized procedures.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Линкомицин Эколинком

Evidence for Serious Systemic or Localized Bacterial Infections

Research has explored the use of Lincomycin for evaluation in serious bacterial infections caused by specific susceptible microorganisms, such as certain types of staphylococci and streptococci. The evidence base for this general application includes various clinical studies, such as comparative and non-comparative trials, which was evaluated in patients. Studies monitored both microbiological outcomes and outcomes related to systemic or functional imbalance, often focusing on short-term symptom changes over defined time intervals.

The medicine was studied for use in various patient groups, including those who have a known allergy to the penicillin class of antibiotics. Studies was evaluated in patients with conditions associated with acute or disruptive episodes, and the research highlights changes measured during the study period.

It is important to understand the context of the evidence. Regulatory documentation indicates that while the medicine was studied for activity against many bacterial strains in the laboratory, official efficacy confirmation has not been confirmed in modern, well-controlled trials for all these organisms. This means that certainty remains low for some of the potentially susceptible organisms.


Evidence for Severe Deep-Seated Infections, Including Bone and Joint Conditions

Research has explored the medicine's use in severe infections involving dense or enclosed tissues, such as those related to bone and joint conditions (like osteomyelitis and septic arthritis). These studies included specialized pharmacokinetic analyses, which monitored the level of the drug that distributes into deep tissues, such as bone and joint fluid. Findings from this work contribute to the broader evidence landscape by describing measurements of tissue availability.

Research in this area often relies on clinical studies and retrospective case series. Studies examined outcomes related to systemic or functional imbalance that were tracked over extended time intervals. Research describes patterns observed in the studies regarding resolution and recurrence in these complex conditions where symptoms may vary in intensity. Research indicates that the drug's concentration in the cerebrospinal fluid (CSF) appears to be inadequate for managing infections such as meningitis, limiting its applicability for all deep-seated infections.


Long-Term Outcomes and Extended Follow-up in Research

Due to the nature of complex infections, particularly in bone and joint tissues, some research was observed in some studies with extended follow-up periods, sometimes lasting multiple years. These observational studies helped contextualize how patients reported their experience regarding long-term outcomes. This extended data shows patterns related to the stability of the clinical situation over time.

However, there is limited information for long-term outcomes from large, contemporary trials designed specifically to track durability. The evidence gathered primarily through observational data applies only to the populations studied in those specific cohorts, and long-term effects are not fully established outside of these specific contexts.


Research in Specific Patient Groups (Special Populations)

The research was evaluated in specific patient sub-groups. For instance, pediatric patients (children older than one month) was studied for this medicine's use in acute episodes. Specialized pharmacokinetic studies explored patterns related to the drug's behavior in patient populations with severe renal or hepatic impairment. While this research contributes to the broader evidence landscape in these specific circumstances, data for certain groups remain insufficient due to the modest sample sizes typically involved in such focused research.


What Remains Uncertain and Research Gaps

The evidence supporting Lincomycin's uses was derived from clinical experience and studies conducted several decades ago. Because of this, evidence quality varies across studies, and many do not meet the standards of rigor applied to new medicines today. The follow-up durations were limited in many of the trials focused on acute systemic infections. Overall, the research describes group patterns, not personal outcomes, and it highlights what is known — and what is still uncertain regarding the full spectrum of its use.

Key Studies & References WHO ATC/DDD Index: J01FF02 (Lincomycin Pharmacological Classification)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Линкомицин Эколинком (FAQ)

Q: Для чего вообще назначают Линкомицин Эколинком?

A: According to official regulatory documents, this medicine is indicated for treating serious infections caused by specific susceptible bacteria, such as certain types of streptococci, pneumococci, and staphylococci. It is noted for its use in individuals who have a known allergy to the penicillin class of antibiotics, as described in product information.

Q: Помогает ли Линкомицин Эколинком при вирусных инфекциях?

A: Official information clarifies that this medicine is an antibacterial, commonly known as an antibiotic. It is only intended for treating infections that have been proven or are strongly suspected to be caused by susceptible bacteria. It is not indicated for, and is generally considered ineffective against, viral infections.

Q: Линкомицин Эколинком и Клиндамицин – это одно и то же?

A: Lincomycin belongs to the same therapeutic class as clindamycin, known as the lincosamides. Due to this structural and functional relationship, official documents state that the medicine is contraindicated (should not be used) if a patient is allergic to clindamycin.

Q: Действительно ли этот препарат используется для лечения зубов?

A: Official product information indicates that this medicine is used to treat various bacterial infections, including those affecting the bones and joints. Its research profile includes study of its distribution into deep tissues, such as those associated with bone and joint infections.

Q: Сколько дней обычно длится курс лечения Линкомицин Эколинком?

A: The length of the course is determined by the specific type and severity of the bacterial infection being treated. Official administration rules specify that, for infections caused by beta-hemolytic streptococci, treatment must be continued for a minimum of 10 full days.

Q: Можно ли прекратить прием Линкомицин Эколинком, если стало лучше?

A: Regulatory warnings indicate that treatment should be continued for the full prescribed duration, even if symptoms improve early. Stopping the medicine too soon increases the risk of the infection returning or the development of drug-resistant bacteria, reducing its future effectiveness.

Q: Есть ли побочные эффекты, о которых нужно знать сразу?

A: Yes, regulatory warnings highlight several serious risks. These include severe allergic reactions, severe or bloody diarrhea that may signal a serious bowel condition (C. difficile colitis), and in rare instances associated with overly rapid intravenous administration, severe cardiac reactions (such as cardiopulmonary arrest) are noted.

Q: Можно ли принимать Линкомицин Эколинком одновременно с другими антибиотиками?

A: Official information states that co-administration with the antibiotic erythromycin and other related macrolides is prohibited because this combination can lead to reduced effectiveness. The use of this medicine with any other antibiotic requires medical assessment.

Q: Взаимодействует ли Линкомицин Эколинком с алкоголем?

A: Although not listed as a formal contraindication in all regulatory sources, consumption of alcohol is noted to be a potential concern during antimicrobial therapy. This is due to the potential for increased gastrointestinal upset, effects on the central nervous system, or potential stress on the liver that can occur with many antibiotics.

Q: Можно ли принимать Линкомицин Эколинком во время беременности?

A: The use of lincomycin during pregnancy should only occur if the potential benefit justifies the potential risk to the fetus, as documented in regulatory guidelines (e.g., Pregnancy Category C). Additionally, official labels note that some injectable forms may contain the preservative benzyl alcohol, which carries specific risks for the developing fetus.

Q: Могут ли пожилые люди принимать Линкомицин Эколинком без особых ограничений?

A: Regulatory precautions recommend caution for use in the elderly population. Patients in this group should be carefully monitored for changes in bowel habits, as official documents indicate an increased risk of severe diarrhea (C. difficile Associated Diarrhea, CDAD).

Q: Влияет ли прием Линкомицин Эколинком на возможность водить машину?

A: The official list of adverse reactions includes reports of dizziness, vertigo (a spinning sensation), and somnolence (drowsiness). Because these effects may impair concentration and judgment, official documents describe the potential for impairment regarding activities like driving or operating heavy machinery.

Q: Нужен ли рецепт, чтобы купить Линкомицин Эколинком?

A: Yes. According to regulatory classifications in various jurisdictions, this medicine is a Prescription Only Medicine (POM). Its use is restricted by federal law to be administered by or on the order of a licensed practitioner.

Q: Может ли Линкомицин Эколинком вызвать головокружение или слабость?

A: Yes, official adverse reaction lists include dizziness and vertigo as reported effects. If a person experiences these symptoms, it is noted that the ability to perform tasks requiring focus, such as driving, may be affected.

Q: Официально ли зарегистрирован Линкомицин Эколинком для лечения той или иной болезни?

A: Yes, regulatory agencies have officially registered this medicine and granted specific indications. It is registered for the treatment of serious infections caused by strains of bacteria that have been identified as susceptible to the drug.

Q: Влияет ли Линкомицин Эколинком на противозачаточные таблетки?

A: Official safety information indicates that lincomycin may reduce the effectiveness of hormonal birth control (oral contraceptives) in some individuals. The need for additional non-hormonal methods of birth control may require further discussion with a healthcare provider.

Q: Что делать, если при приеме Линкомицин Эколинком возникла молочница?

A: Regulatory documentation notes that prolonged use of the drug may result in a fungal superinfection, which can include conditions like vaginal infection (moniliasis/thrush) or other yeasts. This type of secondary infection is noted to potentially require concomitant treatment.

Q: Почему Линкомицин Эколинком классифицируют как линкозамид?

A: The medicine is classified as an antibiotic belonging to the therapeutic class known as the lincosamides. This classification is based on its chemical structure and specifically because of its chemical structure and similar activity to other drugs in that class.

Q: Как долго Линкомицин Эколинком остается в организме после окончания курса?

A: Pharmacokinetic data indicate that the drug's half-life (the time it takes for half of the drug to be eliminated) is typically a few hours in people with normal liver and kidney function. Official sources note that this half-life is significantly prolonged in patients who have severe impairment of the liver or kidneys.

Q: Что такое антибиотикорезистентность в контексте Линкомицин Эколинком?

A: Official warnings emphasize that this medicine should be used only to treat infections caused by susceptible bacteria. This strict usage is necessary to reduce the development of drug-resistant bacteria, which helps maintain the effectiveness of this and other antibacterial drugs.

Q: Что такое анафилактический шок и как он связан с этим лекарством?

A: Anaphylactic shock is documented as a rare, severe allergic reaction (hypersensitivity) that is associated with this medicine. Regulatory information notes that symptoms may include angioedema (swelling) and other signs of a severe, systemic immune response.

Q: Является ли Линкомицин Эколинком препаратом широкого спектра действия?

A: Official product information indicates that this medicine is used to treat infections caused by susceptible strains of only a limited, specific list of bacteria (primarily certain streptococci, pneumococci, and staphylococci). It is generally not classified as a broad-spectrum drug, as it is indicated for a limited list of susceptible strains.

Advertisements

How should Линкомицин Эколинком be stored and disposed of?

Storage and Disposal Requirements

Official regulatory guidelines define mandatory conditions for storing and disposing of Lincomycin (the active ingredient in Линкомицин Эколинком).

Item Regulatory Statement
Storage Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Stability After Opening Multi-dose injection vials must be used within 28 days of first vial broach.
Prohibited Conditions Keep from freezing (for the injection) and protect the container from direct sunlight and sources of ignition.
Child Safety The medicine must be stored out of reach of children.
Disposal Instructions Disposal must follow local, state, and federal regulations. Do not discharge the product to sewer systems; instead, use a licensed chemical destruction plant or controlled incineration.

These statements mandate strict temperature control, container protection, and proper pharmaceutical waste handling to maintain product integrity and prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Линкомицин Эколинком found in:

A-Z Index: